Protocol: NP001-10-002 "A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects with Amyotrophic Lateral Sclerosis (ALS):

Grants and Contracts Details

StatusFinished
Effective start/end date4/15/11 → 10/31/13

Funding

  • Neuraltus Pharmaceuticals Incorporated: $97,941.00